The treatment of hepatic encephalopathy includes reduction of protein intake, alleviation of possible precipitating causes such as haemorrhage, as well as the administration of an antibacterial agent to reduce excessive endogenous, ammonia formation by bacterial decomposition in the gut. Oral neomycin, used to suppress the intestinal flora in both acute and chronic hepatic failure, has been shown experimentally to reduce blood ammonia levels.1 2 However, the use of neomycin is not without hazard, as diarrhoea may be precipitated and there is the slight but definite risk of acute enterocolitis due to an overgrowth of resistant staphylococci or Clostridium dif-.icile.34 During chronic prophylactic administration systemic effects, such as deafness, are possible, as well as steatorrhoea, which can aggravate the nutritional problems.5 6 Neomycin is primarily active against Gramnegative bacilli and staphylococci, and has very limited action against streptococci and anaerobes in general. Yet recent bacteriological studies have suggested the Gram-negative anaerobes make a major contribution to the generation of ammonia from peptides.7 On theoretical grounds it seems likely that metronidazole, which is active against bacteroides and other anaerobes, could also reduce the production of endogenous ammonia by its effect on the anaerobic intestinal flora. In order to test this hypothesis, and to ascertain whether any benefit might ensue in patients with hepatic encephalopathy, a clinical trial was undertaken to compare the effect of metronidazole with that of neomycin.
Received for publication 16 May 1981 Methods Neomycin 1 g, or metronidazole 0-2 g four times a day, were each prescribed separately for one week to patients with acute or chronic encephalopathy. The order of treatment was randomised and was not disclosed to the clinical assessor (MHM Hz was noted after the week on metronidazole, while during the month after this trial her clinical condition failed to improve and she eventually died. Raised blood urea levels may also cause slowing of the EEG and for this reason additional comparison of the treatment regimes was made for 13 of these patients whose blood urea remained normal throughout the trial period. However, even in this smaller group of both severely and moderately affected patients, significant improvement had occurred in the MDF (t=3 00, P<0 01) for neomycin and for metronidazole (t=3.14, P<0O01). Once again it could also be shown that the results were as good after metronidazole as neomycin, with no significant difference evident between the final values for each treatment week.
Mean arterial ammonia levels were greater in group B than in group A, but these differences did not reach statistically significant levels (Mann Whitney U test). treatment, bacteroides could not be detected by the limited methods used. This was also true of one patient given the combination of neomycin and metronidazole. All three regimens were often followed by increases in yeasts and aerobic streptococci which would be resistant to the two agents. Among the severely affected group B patients there were four who received metronidazole first compared with three who received neomycin first, a difference which is unlikely to have exerted a very significant effect on the overall assessment.
Seven of the moderately affected patients had metronidazole first, but in all these there was a delay of at least a week before starting any antibiotics, in order to reduce the possibility of bias.
Seven patients were also prescribed lactulose, but all except one had already received this for at least four weeks before the trial. In addition, four of them received neomycin rather than metronidazole as the first antibiotic. Bowel habit was carefully monitored, and was not significantly different in the metronidazole compared with the neomycin treatment weeks. Only two patients (group B) had enemas, each only one on admission, and one of these had neomycin before metronidazole.
Results of the clinical assessments, EEG analysis, and arterial ammonia estimations for five of the patients in group B who were given a week of combined treatment on neomycin as well as metronidazole are seen in A reduction in the anaerobic flora of the small intestine after metronidazole has previously been demonstrated, but the fall in bacteroides in faeces that we observed in some patients was not seen in volunteers given a metronidazole regimen similar to the one used by us and studied with more elaborate anaerobic bacteriological methods. 27 These authors, however, demonstrated a marked reduction in faecal bacteroides after a combination of neomycin and metronidazole, such as we saw in one patient, and four of our patients who demonstrated a fall in bacteroides counts after metronidazole alone had received neomycin in the previous week. Arabi et al.28 showed a reduction in the coliform count after neomycin in a similar proportion of patients to that seen in the present series.
Thus several theoretical possibilities exist to explain the efficacy of metronidazole in the treatment of hepatic encephalopathy, and the present investigation provides preliminary evidence to suggest that this is a practical alternative. It may, indeed, be a valuable innovation if pseudomembranous enterocolitis caused by Clostridium difficile proves to be a hazard of neomycin treatment.4 The addition of metronidazole to neomycin may further improve the clinical status of patients with encephalopathy. As only a small number of patients has so far received treatment with the combination of drugs it is not possible to draw very firm conclusions. However, the demonstrable improvement in the EEG mean dominant frequency during treatment with the combination, compared with results for either drug alone, suggests that this could be a worthwhile regime to try when either drug alone has failed to produce an adequate clinical response, or when there is apparently diminishing benefit from neomycin.
